CHEST Physician
-
Bronchoscopy: An emerging role for advanced practice providers
Bronchoscopy is becoming an increasingly common skill for a growing subset of interventional pulmonary and critical care APPs.
-
The emerging role of biologic therapy in asthma-COPD overlap
Biologics such as dupilumab, mepolizumab, benralizumab, and tezepelumab are an emerging option for select patients with asthma-COPD overlap, particularly those with T2-high inflammatory phenotypes.
-
Update on the evaluation and management of interstitial lung abnormalities
New guidelines from ATS outline the screening and follow-up procedures for interstitial lung abnormalities as well as define who is at higher risk for progressing to ILD.
-
Bridging Specialties program tackles NTM pulmonary disease and bronchiectasis
CHEST launched Bridging Specialties®: Timely Diagnosis for NTM Pulmonary Disease and Bronchiectasis as a way for PCPs and pulmonologists to collaborate and provide earlier and accurate diagnoses.
-
Top reads from the CHEST journal portfolio – July 2025
Editorial Board members share their insights on journal articles about ato-pima effects on OSA, ccFTD usage after coronary artery bypass grafting, and bronchoscopy in nonintubated patients prior to BAE.
-
COURSE trial shows importance of biomarker testing in COPD
While overall the trial was negative, Meilan King Han, MD, MS, and Sanjay Ramakrishnan, MBBS, PhD, said it demonstrated the promise of tezepelumab for patients with baseline blood eosinophil counts ≥ 150 cells/µL.
-
Procalcitonin levels may guide antibiotic duration in patients with suspected sepsis
Paul Dark, MD, PhD, said a 10% reduction in duration of antibiotic use shown in a recent study may seem small, but in the context of antibiotic stewardship, a 10% reduction is important.
-
Admilparant phase 2 results raise hopes for combination treatment in pulmonary fibrosis
Fernando Martinez, MD, FCCP, said he expects the treatment options for fibrotic lung disease will soon become more complex—in a good way—as more effective therapies become available.
-
Dupilumab reverses airway inflammation, mucus hypersecretion in type 2 asthma
Lead author Mario Castro, MD, MPH, FCCP, said the VESTIGE trial is one of the first to show that we can reverse the disease process in asthma and substantially improve lung function.
-
Hope on the horizon for bronchiectasis
The combination of personalized therapies, novel and repurposed medications, and a multidisciplinary approach is transforming bronchiectasis from a condition that once had few treatment options into one that offers hope for improved management and even disease stabilization.
